Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Nature Medicine

• Publication date

  2000-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/79558PMID 10973326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

  1999cited by this paper
• Erratum: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations

  1998cited by this paper
• Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

  1998cited by this paper
• Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid

  1998cited by this paper
• Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography.

  1998cited by this paper
• In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide

  1998cited by this paper
• Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• Biochemistry and molecular genetics of cell‐wall lipid biosynthesis in mycobacteria

  1997cited by this paper
• The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol

  1997cited by this paper
• Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis

  1997cited by this paper
• Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis

  1996cited by this paper
• Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

  1996cited by this paper
• Cloning, sequencing and characterization of a fatty acid synthase-encoding gene from Mycobacterium tuberculosis var. bovis BCG.

  1996cited by this paper
• Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.

  1995cited by this paper
• Analysis of mycolic acids by high-performance liquid chromatography and fluorimetric detection. Implications for the identification of mycobacteria in clinical samples.

  1995cited by this paper
• inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

  1994cited by this paper
• Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

  1994cited by this paper
• Purification and characterization of an unusually large fatty acid synthase from Mycobacterium tuberculosis var. bovis BCG.

  1992cited by this paper
• Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.

  1990cited by this paper
• The role of pyrazinamide in tuberculosis chemotherapy.

  1988cited by this paper
• Identification and drug susceptibility test results for Mycobacterium spp.

  1985cited by this paper
• The action of antituberculosis drugs in short-course chemotherapy.

  1985cited by this paper
• The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

  1978cited by this paper
• [10] Fatty acid synthases from Mycobacterium phlei

  1975cited by this paper
• Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis.

  1975cited by this paper
• Fatty acid synthases from Mycobacterium phlei.

  1975cited by this paper
• Mycobacterium phlei Fatty Acid Synthetase—A Bacterial Multienzyme Complex

  1969cited by this paper
• Experimental chemotherapy of tuberculosis.

  1968cited by this paper
• Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

  1967cited by this paper
• A simple method for the isolation and purification of total lipides from animal tissues.

  1957cited by this paper
• THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE

  1956cited by this paper
• Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

  1954cited by this paper
• Experimental Chemotherapy of Tuberculosis. II. The Synthesis of Pyrazinamides and Related Compounds1

  1952cited by this paper
• Chemistry of the Lipoids of Tubercle Bacilli

  1930cited by this paper
• THE CHEMISTRY OF THE LIPOIDS OF TUBERCLE BACILLI VIII. CONCERNING THE UNSAPONIFIABLE WAX

  1929cited by this paper

• Contribution of Proteins to Membrane and Cell Wall Structures in Mycobacterium tuberculosis.

  2026cites this paper
• Inhalable Pyrazinamide Loaded Lipid Polymer Hybrid Nanoparticles: In vitro and In vivo Lung Deposition Studies

  2025cites this paper
• Inhibition of de novo fatty acid synthesis in Mycobacterium tuberculosis

  2025cites this paper
• Pyrazinamide kills Mycobacterium tuberculosis via pH-driven weak-acid permeation and cytosolic acidification

  2025cites this paper
• Structural Characterisation, Anticancer Properties, and BSA Binding of 2,6-Dipyrazinylpyridines: Insights from Experiment and Theory

  2025cites this paper
• Role of Different Isoniazid Analogs as Antitubercular Agents

  2025cites this paper
• EFFECT OF PEGYLATED POLYPROPYLENE IMINE DENDRITIC ARCHITECTURE ON PHARMACOKINETICS OF PYRAZINAMIDE ON RABBITS

  2024cites this paper
• Mechanism of the dual action self-potentiating antitubercular drug morphazinamide

  2024cites this paper
• Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis

  2024cites this paper
• Aerosolizable Pyrazinamide-Loaded Biodegradable Nanoparticles for the Management of Pulmonary Tuberculosis

  2024influential citation
• Natural Products–Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry

  2023cites this paper
• A liquid chromatography-tandem mass spectrometry method development for the quantification of favipiravir drug and its related impurities in rat plasma and its application to pharmacokinetic studies.

  2023cites this paper
• Optimization of Nitration of 3-Hydroxypyrazine-2-Carboxamide to 3-Hydroxy-6-Nitropyrazine-2-Carboxamide

  2023cites this paper
• Clinical strains of Mycobacterium tuberculosis exhibit differential lipid metabolism-associated transcriptome changes in in vitro cholesterol and infection models

  2022cites this paper
• Molecular insights of hyaluronic acid – ethambutol and hyaluronic acid – isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis

  2022cites this paper
• Pyrimidine derivatives with antitubercular activity.

  2022cites this paper
• Synthesis of Coumarin-Thioether Conjugates as Potential Anti-Tubercular Agents: Their Molecular Docking and X-Ray Crystal Studies

  2022cites this paper
• Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.

  2022cites this paper
• Structural insights of the elongation factor EF-Tu complexes in protein translation of Mycobacterium tuberculosis

  2022cites this paper
• Pyrazinamide Analogs Designed for Rational Drug Designing Strategies against Resistant Tuberculosis

  2022cites this paper
• Activity of Pyrazinamide against Mycobacterium tuberculosis at Neutral pH in PZA-S1 Minimal Medium

  2021cites this paper
• Structure-Aware Mycobacterium tuberculosis Functional Annotation Uncloaks Resistance, Metabolic, and Virulence Genes

  2021cites this paper
• The 7H11 Agar Medium Supplemented with Calf Bovine Serum for Susceptibility Testing of Mycobacterium tuberculosis Isolates Against Pyrazinamide

  2021cites this paper
• Identification of Novel Inhibitors of Type-I Mycobacterium Tuberculosis Fatty Acid Synthase Using Docking-Based Virtual Screening and Molecular Dynamics Simulation

  2021influential citation
• The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors

  2021cites this paper
• Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China

  2021cites this paper
• Not too fat to fight: The emerging role of macrophage fatty acid metabolism in immunity to Mycobacterium tuberculosis

  2021cites this paper
• Identification of Novel Inhibitors of Type-I Mycobacterium Tuberculosis Fatty Acid Synthase Using Docking-Based Virtual Screening and Molecular Dynamics Simulation

  2021cites this paper
• A computational perspective on the dynamic behaviour of recurrent drug resistance mutations in the pncA gene from Mycobacterium tuberculosis

  2021cites this paper
• A Comprehensive Review onMycobacterium tuberculosisTargets and Drug Development from a Structural Perspective

  2020cites this paper
• The Bewildering Antitubercular Action of Pyrazinamide

  2020influential citation
• Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies.

  2020cites this paper
• Structural insights of catalytic mechanism in mutant pyrazinamidase of Mycobacterium tuberculosis

  2020cites this paper
• Tuberculosis - present medication and therapeutic prospects.

  2020cites this paper
• The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD

  2020cites this paper
• Tuberculosis vertebral del adulto

  2020cites this paper
• EXPRESSION OF Mycobacterium tuberculosis RpsA IN Mycobacterium smegmatis INCREASES SUSCEPTIBILITY TO PYRAZINAMIDE

  2020cites this paper
• Mycobacterium smegmatis msmeg_3314 is involved in pyrazinamide and fluoroquinolones susceptibility via NAD+/NADH dysregulation.

  2020cites this paper
• Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid

  2020cites this paper
• N-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents—the Synthesis and Biological Evaluation of Enantiomers

  2020cites this paper
• The Forgotten Pyrazines: Exploring the Dakin-West Reaction.

  2020cites this paper
• Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.

  2020cites this paper
• Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

  2019influential citation
• Genetics and roadblocks of drug resistant tuberculosis.

  2019cites this paper
• Médicaments et molécules innovantes en développement pour la prise en charge de la tuberculose

  2019cites this paper
• Anti‐tuberculosis Agents

  2019cites this paper
• Nano-antimicrobials: A new paradigm for combating mycobacterial resistance.

  2019cites this paper
• A one-pot and three-component synthetic approach for the preparation of asymmetric and multi-substituted 1,4-dihydropyrazines

  2019cites this paper
• Derivatives of 3-Aminopyrazine-2-carboxamides: Synthesis, Antimicrobial Evaluation, and in Vitro Cytotoxicity

  2019cites this paper
• Nutrient Depletion and Bacterial Persistence

  2019cites this paper
• Characterizing phenotypes of Mycobacterium tuberculosis and exploring anti-mycobacterial compounds through high content screening

  2019cites this paper
• Impact of the host environment on the antitubercular action of pyrazinamide

  2019cites this paper
• Fabrication of sensors for the sensitive electrochemical detection of anti-tuberculosis drugs

  2018cites this paper
• Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance

  2018cites this paper
• Anti-Sporothrix brasiliensis activity of different pyrazinoic acid prodrugs: a repurposing evaluation

  2018cites this paper
• Targeting the Proteostasis Network for Mycobacterial Drug Discovery

  2018cites this paper
• Effect of A Standard Anti Parameters and Serum Protein Level in Male Wistar R

  2018cites this paper
• Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution

  2018cites this paper
• Preparation of new halogenated diphenyl pyrazine analogs in Escherichia coli by a mono-module fungal nonribosomal peptide synthetase from Penicillium herquei

  2018cites this paper
• Structure-aware M. tuberculosis functional annotation uncloaks resistance, metabolic, and virulence genes

  2018cites this paper
• Pyrazinoates as antiparasitic agents against Trypanosoma cruzi

  2018cites this paper
• Hepatoprotective Activity of Hedyotis corymbosa (Linn.) Lam. Extract Against Anti-Tubercular Drug Induced Hepatic Damage in Sprague-Dawley Rats

  2018cites this paper
• Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents

  2018cites this paper
• Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care

  2018cites this paper
• Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

  2018cites this paper
• Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli

  2018influential citation
• Synthesis and evaluation of novel coumarin-oxime ethers as potential anti-tubercular agents: Their DNA cleavage ability and BSA interaction study.

  2018cites this paper
• Hit Generation in TB Drug Discovery: From Genome to Granuloma

  2018cites this paper
• Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold.

  2018cites this paper
• Learning from the past for TB drug discovery in the future.

  2017cites this paper
• Mechanisms of Drug Action, Drug Resistance and Drug Tolerance in Mycobacterium tuberculosis: Expected Phenotypes from Evolutionary Pressures from a Highly Successful Pathogen

  2017cites this paper
• Synthesis, biological evaluation, molecular docking, and ADMET studies of some isoxazole-based amides

  2017cites this paper
• The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography

  2017cites this paper
• QSAR based therapeutic management of M. tuberculosis

  2017cites this paper
• Emerging drugs and drug targets against tuberculosis

  2017cites this paper
• The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot

  2017cites this paper
• Antimycobacterial Agents: To Target or Not to Target

  2017cites this paper
• Strategies for Tackling Drug Resistance in Tuberculosis

  2017cites this paper
• Management of Ocular Tuberculosis

  2017cites this paper
• QSAR based therapeutic management of M. tuberculosis

  2017cites this paper
• Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA

  2017cites this paper
• Ocular Tuberculosis

  2017cites this paper
• Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis

  2017cites this paper
• 148 – Antituberculosis Agents

  2017cites this paper
• Targeting Phenotypically Tolerant Mycobacterium tuberculosis

  2017cites this paper
• Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.

  2017cites this paper
• Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era.

  2017cites this paper
• Mechanisms of Action and Resistance of the Antimycobacterial Agents

  2017cites this paper
• Studien zum Einsatz von enzymatischen Lewis- und Brønsted-Säuren in Carbonyl-aktiviertenorganischen Reaktionen

  2016cites this paper
• Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis.

  2016cites this paper
• Identification of M. tuberculosis pncA gene single nucleotide polymorphisms conferring resistance to pyrazinamide.

  2016cites this paper
• Drug-Resistant Tuberculosis: Challenges and Progress.

  2016cites this paper
• A SIRT4-like auto ADP-ribosyltransferase is essential for the environmental growth of Mycobacterium smegmatis.

  2016cites this paper
• Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis

  2016cites this paper
• Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

  2016cites this paper
• Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis

  2016cites this paper
• Fighting drug-resistant tuberculosis:CTP-synthetase and pantothenate kinase as new targets for multitargeting compounds.

  2016cites this paper
• The preparation of artemisinin-cholesterol conjugates as potential new drugs for treatment of intractable forms of tuberculosis and malaria

  2016cites this paper
• Heterogeneous behavior of metalloproteins toward metal ion binding and selectivity: insights from molecular dynamics studies

  2016cites this paper
• Mycobacterial (Skin) Infections

  2016cites this paper